PRDX1 and cancer: However, considering the molecular progression of the abovementioned cancers and clinically confirmed treatments, it is more likely that a combinatorial application of PCNA with some transcription regulators, coregulators, and enzymes, such as nuclear insulin-like growth factor-1 receptor, bone morphogenetic protein endothelial cell precursor-derived regulator, CD24, B7-H4, histone deacetylases, peroxiredoxin 1, P21, and P53, will be effective for the diagnosis of gynecological cancers at different stages.